Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Jeffrey Curtis, MD, MS, MPH

University of Alabama at Birmingham
Hoover, AL, United States

Dr. Jeffrey Curtis is a Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). Dr. Curtis received a Medical Degree (MD) and a Master of Public Health (MPH) degree from Oregon Health & Sciences University in Portland, OR. He subsequently completed a residency in internal medicine at Oregon Health & Science University and a fellowship in rheumatology at UAB. He completed a graduate program in Clinical Informatics at Stanford University and received his Master of Science (MS) degree in epidemiology at the Harvard School of Public Health. He is board certified in both rheumatology and clinical informatics.

Dr. Curtis holds the Harbert-Ball Endowed Professorship in Rheumatology and Immunology at UAB. His major research emphasis is on evaluating the safety and comparative effectiveness of medications for rheumatic diseases. He also conducts both investigator-initiated and industry-sponsored clinical trials in rheumatoid arthritis (RA) and spondyloarthritis (SpA), including large pragmatic trials. He is the PI of the UAB P30 Informatics Core funded by NIH (NIAMS), focused on digital health and ‘big data’ in musculoskeletal diseases.

Presentation(s):

  • 0530: Impact of Upadacitinib on Wearable Device-Measured Physical Activity in Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Trial

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); CorEvitas: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly and Company: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Myriad: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing)

  • 0718: Clinical and Economic Burden of Polymyalgia Rheumatica in Patients with an Inadequate Response to Glucocorticoids in a Real-World Setting

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); CorEvitas: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly and Company: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Myriad: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing)

  • 13M162: Abstracts: Infection-related Rheumatic Disease (1669–1674)

    Monday, November 13, 2023
    4:00 PM – 5:30 PM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); CorEvitas: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly and Company: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Myriad: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing)

  • 1673: Immunomodulatory Treatment and Autoimmune Patient Responses to COVID-19 Booster Shots: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study

    Monday, November 13, 2023
    5:00 PM – 5:10 PM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); CorEvitas: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly and Company: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Myriad: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing)

  • 2008: Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

    Tuesday, November 14, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); CorEvitas: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly and Company: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Myriad: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing)

  • 2025: Osteoporosis Treatment Attributes and Levels for an Online Decision-Making Tool for Patients: Findings from Adaptive Choice-Based Conjoint Analysis

    Tuesday, November 14, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); CorEvitas: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly and Company: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Myriad: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing)

  • 2236: Guselkumab Provides Rapid Clinically Meaningful Improvements in Clinical and Patient Reported Outcomes and Sustained Disease Control of Psoriatic Arthritis

    Tuesday, November 14, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); CorEvitas: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly and Company: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Myriad: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing)

  • Improvement of Rheumatoid Arthritis Care Efficiency via an Integrated App

    Tuesday, November 14, 2023
    2:15 PM – 2:30 PM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); CorEvitas: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly and Company: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Myriad: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing)

  • 2529: Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

    Tuesday, November 14, 2023
    4:30 PM – 4:40 PM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); CorEvitas: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly and Company: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Myriad: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing)